CONTEXT: -Colorectal carcinoma is the third most common cause of cancer death in males and females in the United States. Rectal adenocarcinoma can have distinct therapeutic and surgical management from colonic adenocarcinoma owing to its location and anatomic considerations. OBJECTIVE: -To determine the oncologic driver mutations and better understand the molecular pathogenesis of rectal adenocarcinoma in relation to colon adenocarcinoma. DESIGN: -Next-generation sequencing was performed on 20 cases of primary rectal adenocarcinoma with a paired lymph node or solid organ metastasis by using an amplicon-based assay of more than 2800 Catalogue of Somatic Mutations in Cancer (COSMIC)-identified somatic mutations. RESULTS: -Next-generation sequencing data were obtained on both the primary tumor and metastasis from 16 patients. Most rectal adenocarcinoma cases demonstrated identical mutations in the primary tumor and metastasis (13 of 16, 81%). The mutations identified, listed in order of frequency, included TP53, KRAS, APC, FBXW7, GNAS, FGFR3, BRAF, NRAS, PIK3CA, and SMAD4. CONCLUSIONS: -The somatic mutations identified in our rectal adenocarcinoma cohort showed a strong correlation to those previously characterized in colonic adenocarcinoma. In addition, most rectal adenocarcinomas harbored identical somatic mutations in both the primary tumor and metastasis. These findings demonstrate evidence that rectal adenocarcinoma follows a similar molecular pathogenesis as colonic adenocarcinoma and that sampling either the primary or metastatic lesion is valid for initial evaluation of somatic mutations and selection of possible targeted therapy.
CONTEXT: -Colorectal carcinoma is the third most common cause of cancer death in males and females in the United States. Rectal adenocarcinoma can have distinct therapeutic and surgical management from colonic adenocarcinoma owing to its location and anatomic considerations. OBJECTIVE: -To determine the oncologic driver mutations and better understand the molecular pathogenesis of rectal adenocarcinoma in relation to colon adenocarcinoma. DESIGN: -Next-generation sequencing was performed on 20 cases of primary rectal adenocarcinoma with a paired lymph node or solid organ metastasis by using an amplicon-based assay of more than 2800 Catalogue of Somatic Mutations in Cancer (COSMIC)-identified somatic mutations. RESULTS: -Next-generation sequencing data were obtained on both the primary tumor and metastasis from 16 patients. Most rectal adenocarcinoma cases demonstrated identical mutations in the primary tumor and metastasis (13 of 16, 81%). The mutations identified, listed in order of frequency, included TP53, KRAS, APC, FBXW7, GNAS, FGFR3, BRAF, NRAS, PIK3CA, and SMAD4. CONCLUSIONS: -The somatic mutations identified in our rectal adenocarcinoma cohort showed a strong correlation to those previously characterized in colonic adenocarcinoma. In addition, most rectal adenocarcinomas harbored identical somatic mutations in both the primary tumor and metastasis. These findings demonstrate evidence that rectal adenocarcinoma follows a similar molecular pathogenesis as colonic adenocarcinoma and that sampling either the primary or metastatic lesion is valid for initial evaluation of somatic mutations and selection of possible targeted therapy.
Authors: Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput Journal: Clin Colorectal Cancer Date: 2019-02-13 Impact factor: 4.481
Authors: Mariana Petaccia de Macedo; Fernanda M Melo; Heber Salvador C Ribeiro; Marcio C Marques; Luciane T Kagohara; Maria Dirlei Begnami; Julio C Neto; Júlia S Ribeiro; Fernando A Soares; Dirce M Carraro; Isabela W Cunha Journal: Am J Cancer Res Date: 2017-09-01 Impact factor: 6.166
Authors: In Hee Lee; Keunsoo Kang; Byung Woog Kang; Soo Jung Lee; Woo Kyun Bae; Jun Eul Hwang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim Journal: Med Oncol Date: 2018-09-11 Impact factor: 3.064
Authors: Thomas Schweiger; Sandra Liebmann-Reindl; Olaf Glueck; Patrick Starlinger; Johannes Laengle; Peter Birner; Walter Klepetko; Dietmar Pils; Berthold Streubel; Konrad Hoetzenecker Journal: J Thorac Dis Date: 2018-11 Impact factor: 2.895
Authors: Elena Fountzilas; Vassiliki Kotoula; Ioannis Tikas; Kyriaki Manousou; Kyriaki Papadopoulou; Christos Poulios; Vasilios Karavasilis; Ioannis Efstratiou; Dimitrios Pectasides; Kleo Papaparaskeva; Ioannis Varthalitis; Christos Christodoulou; George Papatsibas; Sofia Chrisafi; Georgios K Glantzounis; Amanda Psyrri; Gerasimos Aravantinos; Georgia-Angeliki Koliou; George K Koukoulis; George E Pentheroudakis; George Fountzilas Journal: Oncotarget Date: 2018-11-02
Authors: Shinkyo Yoon; Miso Kim; Yong Sang Hong; Han Sang Kim; Seung Tae Kim; Jihun Kim; Hongseok Yun; Changhoon Yoo; Hee Kyung Ahn; Hyo Song Kim; In Hee Lee; In-Ho Kim; Inkeun Park; Jae Ho Jeong; Jaekyung Cheon; Jin Won Kim; Jina Yun; Sun Min Lim; Yongjun Cha; Se Jin Jang; Dae Young Zang; Tae Won Kim; Jin Hyoung Kang; Jee Hyun Kim Journal: Cancer Res Treat Date: 2021-12-13 Impact factor: 4.679
Authors: Snehal B Patel; Robert Bookstein; Navid Farahani; Myriam Chevarie-Davis; Andy Pao; Angela Aguiluz; Christian Riley; Jennelle C Hodge; Serhan Alkan; Zhenqui Liu; Nan Deng; Jean R Lopategui Journal: Oncol Ther Date: 2021-04-25
Authors: Valentina Kovaleva; Anna-Lena Geissler; Lisa Lutz; Ralph Fritsch; Frank Makowiec; Sebastian Wiesemann; Ulrich T Hopt; Bernward Passlick; Martin Werner; Silke Lassmann Journal: Mol Cancer Date: 2016-10-18 Impact factor: 27.401